Entera Bio Moves Toward Phase 3 With Oral Therapy That Could Transform Osteoporosis Treatment (NASDAQ: ENTX)

As Washington pushes cheaper medicines through TrumpRx, Mark Cuban challenges the pharmaceutical middlemen, and big pharma pours billions into oral peptide technologies, Entera Bio ( NASDAQ:ENTX) is ...
GovCon Wire

GSA Unveils 43 Phase 1 Awardees for Alliant 3 GWAC

The Alliant 3 awards build on GSA’s long-running Alliant contract lineage. In 2017, GSA selected 80 companies for the small business track of a potential 10-year, $15 billion Alliant 2 IT GWAC vehicle ...

Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of ...

Merck Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL), a Once-Daily, Two-Drug Regimen at CROI 2026 ...
Agence France-Presse

Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis

Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO ® (vedolizumab) can offer the possibility of clinical remission for ...
pharmaphorum

Roche preps phase 3 for 'Brainshuttle' Alzheimer's drug

Buoyed by new results from a phase 1b/2a trial, Roche has said it plans to start a phase 3 programme for an Alzheimer's disease candidate from its Brainshuttle programme, a technology designed to help ...
pharmaphorum

UCB, Biogen lupus drug scores in phase 3 trial

UCB and Biogen say their first phase 3 trial of their systemic lupus erythematosus (SLE) candidate dapirolizumab pegol was a success, and a second is now expected to start before the end of the year.
The Caledonian-Record

New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech’s Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that a detailed analysis of the Phase III ALLEGORY trial of Gazyva ® (obinutuzumab) in adults with systemic lupus ...

Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology

Delcath Systems, Inc. (Nasdaq: DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication ...
PharmiWeb

Vico Therapeutics Announces Patient Dosing in Twice-Annual Regimen of VO659 in Phase 1/2 Trial in Huntington’s Disease, Spinocerebellar Ataxia Type 3 and Type 1

FDA clearance of IND application for VO659 with plans to initiate US-based clinical trial later this yearNew data highlight distinctive mechanism of action of exon 1–directed CAG repeat–targeting ASO ...
The Daily Reflector

TomaGold Initiates Major Phase 2 Program at Berrigan Mine to Test Berrigan Deep Potential Through Extension Drilling and 4 km by 2 km Deep Geophysical Survey

Figure 1 - Longitudinal view of the Phase 2 extension drilling program at Berrigan Mine: 3D longitudinal section showing ...
PharmiWeb

Genentech's Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)

FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with ...